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Abstract
Background Pro-thrombotic conditions importantly influ-
ence myocardial perfusion and procedural results after per-
cutaneous coronary intervention (PCI). The neutrophil-to-
lymphocyte ratio (NLR) has emerged as a predictor of car-
diovascular events and of long-term prognosis, especially
in ST-elevation myocardial infarction patients undergoing
primary PCI. The aim of our study was to evaluate the role
of NLR on periprocedural myocardial infarction (MI) in
patients undergoing non-urgent PCI.
Methods In a consecutive cohort of 1542 patients undergo-
ing PCI, myonecrosis biomarkers were determined at 6, 12,
24 and 48 hours post-procedure. Patients were divided into
quintiles according to NLR values. Periprocedural myo-
necrosis was defined as a troponin I increase of 3 times the
upper limit of normal or as 50 % of an elevated baseline
value, whereas periprocedural MI was defined as a CK-MB
increase of 3 times the upper limit of normal or 50 % of
baseline.
Results Higher NLR was related to age, established risk
factors and cardiovascular history. NLR was associated
with severe coronary artery disease (p = 0.009), tighter
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stenosis (p < 0.001), coronary calcifications (p = 0.005),
intracoronary thrombus or thrombectomy use (p < 0.001),
TIMI flow pre- and post-PCI (p < 0.001), and inversely to
restenosis (p = 0.04) and use of a drug-eluting stent (p =
0.001). NLR did not influence the occurrence of myonecro-
sis (p = 0.75; adjusted OR (95 % CI) = 0.99 (0.63–1.54),
p = 0.96), but was associated with a higher occurrence of
periprocedural MI, even after correction for baseline differ-
ences (p = 0.03; adjusted OR (95 % CI) = 1.33 (1.02–2.3),
p = 0.02), with NLR ≥ 3 best predicting the risk of peripro-
cedural MI at the receiver operating characteristic curve
analysis.
Conclusion In patients undergoing non-urgent PCI, a higher
NLR increases the risk of periprocedural MI, especially for
values ≥ 3.
Keywords Neutrophil/lymphocyte ratio · White blood
cells · PCI · Periprocedural myocardial infarction
Background
Technological improvements and the introduction of new,
more potent, antithrombotic therapies [1–3] have allowed
an escalation in the complexity of percutaneous coronary
interventions (PCI), therefore enhancing the risk of peripro-
cedural complications [4, 5].
In fact, many patients still suffer a periprocedural myo-
cardial infarction (MI), especially as a consequence of flow-
limiting complications, although a myocardial injury can
also occur silently, due to the formation of leukocyte and
platelet plugs in the microvascular circulation, preventing
myocardial perfusion and potentially negatively influencing
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Fig. 1 Flow chart for patient inclusion and study procedures
Fig. 3 Bar graph showing the prevalence of periprocedural my-
onecrosis according to neutrophil to lymphocyte ratio (NLR) quintiles
values
tory status can be involved in these events, enhancing pro-
thrombotic response and platelet reactivity.
The neutrophil-to-lymphocyte ratio (NLR) has recently
emerged among the markers of inflammation, being an in-
expensive, easy to obtain parameter, which can improve the
risk stratification of patients with cardiovascular disease [7].
In fact, it has been associated with arterial stiffness and with
the indicators of the extent of coronary artery disease [8, 9],
and moreover with thrombus formation in acute coronary
syndromes [10]. In these settings NLR has been suggested
to influence short-term and long-term outcome, especially
in patients with ST-segment elevation myocardial infarction
(STEMI) undergoing primary PCI [11, 12]. However, no
study has so far evaluated its impact in patients undergoing
non-urgent percutaneous coronary revascularization. The
aim of our study was, then, to assess whether NLR can in-
fluence the risk of periprocedural MI in patients undergoing
non-urgent PCI.
Fig. 2 Bar graph showing the prevalence of periprocedural myocar-
dial infarction according to neutrophil to lymphocyte ratio (NLR) quin-
tiles values
Methods
We included patients undergoing coronary angioplasty at
Ospedale “Maggiore della Carità” from May 2007 to Jan-
uary 2013 for both elective indications or acute coronary
syndromes (unstable angina/NSTEMI). NSTEMI patients
were defined by the presence of chest pain and cardiac
biomarkers elevation above the upper limit of normality
(0.04 µg/l for troponin I and 5.00 µg/l for CK-MB, respec-
tively) and underwent elective coronary angiography after
pharmacological stabilisation, but not STEMI and unstable
patients requiring urgent angioplasty.
Diabetes mellitus was defined as one of the following:
1) previous diagnosis, 2) specific treatment of diabetes (oral
or insulin), 3) fasting glycaemia > 126 mg/dl in at least two
repeated determinations, 4) or HbA1c > 6.5 %. Hyperten-
sion was defined as a systolic pressure > 140 mmHg and/or
diastolic pressure > 90 mmHg or if the individual was tak-
ing antihypertensive medications [13].
The study was approved by our local ethics commit-
tee. In accordance with the guidelines, all patients received
a bolus of an antiplatelet adenosine diphosphate antagonist
at the time of hospitalisation or before angioplasty. Patients
were clinically followed up to hospital discharge.
Biochemical measurements
Blood samples were drawn at admission (following a fast-
ing period of 12 hours) in patients undergoing coronary
angiography for elective or acute indications. Glucose, cre-
atinine, HbA1c and lipid profile were determined by stan-
dard methods. The total and differential white blood cell
count was measured in a blood sample collected in tri-
potassium EDTA (7.2 mg) tubes. These blood samples
were analysed within 2 hours of venepuncture by an au-
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Fig. 4 Receiver-operating characteristic (ROC) curve for the neu-
trophil to lymphocyte ratio (NLR) values in the prediction of peripro-
cedural myocardial infarction
tomatic blood counter (Sysmex XE-2100) used for whole
blood analysis. The neutrophil/lymphocyte ratio was mea-
sured for each patient. Cardiac biomarkers (troponin I and
CK-MB) were measured at baseline, before coronary revas-
cularization, and later at 6, 12, 24 and 48 hours after PCI.
Coronary angiography and PCI
Coronary angiography was routinely performed by the Jud-
kins technique using 6-French catheters. Quantitative coro-
nary angiography was performed by experienced interven-
tional cardiologists using an automatic edge-detection sys-
tem (Siemens Acom Quantcor QCA, Erlangen, Germany)
[14]. Coronary angioplasty was performed with standard
techniques. All patients received a bolus of unfraction-
ated heparin during coronary angiography (80 U/kg) and
if needed additional heparin was administered during the
procedure according to the activated clotting time. An
oral loading dose of an adenosine diphosphate antagonist
(600 mg clopidogrel or 180 mg ticagrelor) was given before
PCI, if the patient had not already been pre-treated with oral
dual-antiplatelet therapy.
Use of stents, type of stents and stent implantation
techniques, as well as the use of directional or rotational
atherectomy, intravascular ultrasound, and glycoprotein IIb/
IIIa inhibitors, was left to the discretion of the operators.
Study endpoints
The primary study endpoint was periprocedural MI defined
as CK-MB mass value ≥ 3 times the upper limit normal or
an increase of 50 % of baseline value if already elevated,
but stable or falling, at the time of the procedure. The
secondary study endpoint was a periprocedural increase in
troponin I ≥ 3 times the upper limit normal or an increase
of 50 % of the preprocedural value, if >0.04 ng/ml. In
addition, the most recent definition of periprocedural MI as
a troponin I increase of 5 times the upper limit normal or
20 % of a baseline elevated value was also used.
Statistical analysis
Statistical analysis was performed using the SPSS 17.0 sta-
tistical package. Patients were divided into quintiles accord-
ing to NLR values (<1.7; 1.7–2.19; 2.20–2.89; 2.9–4.19;
≥4.2). Continuous data are expressed as mean ± SD and
categorical data as percentages. Analysis of variance and
the chi-square test (or Fisher’s test) were used for continu-
ous and categorical variables, respectively. Multiple logistic
regression analysis was performed to evaluate the relation-
ship between NLR and periprocedural myocardial necrosis
or infarction, after correction for clinical and angiographic
significant differences, which were entered in the model in
block. Receiver-operating characteristic (ROC) curve anal-
ysis was performed to identify the best predicting value for
periprocedural MI.
Results
Our population consisted of 1542 patients; 1084 were di-
agnosed with acute coronary syndrome, while 458 were
stable patients scheduled for PCI. The flowchart for patient
selection is shown in Fig. 1.
As shown in Tab. 1, higher NLR was related to age (p
< 0.001), hypertension (p = 0.02), hypercholesterolaemia
(p < 0.001), acute coronary syndrome at admission (p =
0.003), use of diuretics (p = 0.001), glycaemia, creatinine,
fibrinogen, C-reactive protein and white blood cell count (p
< 0.001), and inversely with smoking (p = 0.001), previous
PCI (< 0.001), treatment with beta-blockers, statins and
acetylsalicylic acid and haemoglobin values (p < 0.001).
Tab. 2 displays the main angiographic characteristics and
procedural features. NLR was associated with more se-
vere coronary artery disease (p = 0.009), tighter stenosis (p
< 0.001), coronary calcifications (p = 0.005), intracoronary
thrombus or need for thrombectomy (p < 0.001), TIMI flow
pre- and post-PCI (p < 0.001), and inversely with restenosis
(p = 0.04) and use of drug-eluting stent (DES) (p = 0.001).
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Fig. 5 Bar graph showing the prevalence of periprocedural myocar-
dial infarction in patients with neutrophil to lymphocyte ratio (NLR)
≥ 3
NLR was associated to a higher occurrence of peripro-
cedural MI (17.3 vs 16.6 vs 14.1 vs 19.9 vs 23.5 %, p =
0.03, OR (95 % CI) = 1.11 (1.01–1.22), p = 0.03), as dis-
played in Fig. 2, but did not influence the occurrence of
myonecrosis (61.5 vs 60.9 vs 66.6 vs 63.2 vs 61.8 %, p =
0.75; OR (95 % CI) = 1.01 (0.94–1.09), p = 0.75; Fig. 3).
The results were maintained after correction for base-
line differences (age, hypertension, hypercholesterolaemia,
acute coronary syndrome, treatment with beta-blockers,
statins, acetylsalicylic acid and diuretics, glycaemia, crea-
tinine, fibrinogen, C-reactive protein, haemoglobin, white
blood cell count, smoking, previous PCI, severity of coro-
nary artery disease, % stenosis, coronary calcifications,
intracoronary thrombus, thrombectomy, TIMI flow pre-
and post-PCI, restenosis and use of DES), for both myo-
necrosis (adjusted OR (95 % CI) = 0.99 (0.63–1.54), p =
0.96), and periprocedural MI (adjusted OR (95 % CI) =
1.33 (1.02–2.3), p = 0.02) and also when considering
NLR as a continuous variable (myonecrosis: adjusted OR
(95 % CI) = 1.01 (0.97–1.06), p = 0.63; periprocedural MI:
adjusted OR (95 % CI) = 1.05 (1.001–1.10), p = 0.05).
At ROC curve analysis, NLR ≥ 3 proved to have the best
predictive value for the risk of periprocedural MI (AUC
0.544, p = 0.03, Fig. 4), and in fact, when dividing our pa-
tients for NLR < or ≥ 3, a higher rate of periprocedural MI
was found in patients with elevated NLR (15.8 vs 22.3 %,
p = 0.02, adjusted OR (95 % CI) = 1.39 (1.03–1.88), p =
0.03, as shown in Fig. 5).
Analogous results were achieved when separately con-
sidering acute coronary syndrome (n = 1084) and stable
patients (n = 458). In fact, among acute patients, an in-
creased rate of periprocedural MI was observed for NLR
≥ 3 (periprocedural MI: 28.1 vs 20.7 %, p = 0.03; adjusted
OR (95 % CI) = 1.53 (1.01–2.3), p = 0.04; myonecrosis:
57.6 vs 56.6 %, p = 0.82; adjusted OR (95 % CI) = 1.05
(0.67–1.63), p = 0.84). On the contrary, among patients
with stable coronary artery disease, we confirmed a simi-
lar occurrence of myonecrosis according to NLR < or ≥ 3
(70.3 vs 67.5 %, p = 0.48; adjusted OR (95 % CI) = 1.21
(0.63–2.31), p = 0.57) whereas we observed an absolute in-
crease in the rate of periprocedural MI (19.2 vs 13.7 %, p =
0.22), although not reaching statistical significance at mul-
tivariate analysis (adjusted OR (95 % CI) = 2.2 (0.94–4.9),
p = 0.07).
Results did not change when applying a more recent
definition of periprocedural MI (troponin I > 5 x upper limit
normal or 20 % of baseline value), with a trend for higher
periprocedural myocardial injury in patients with NLR ≥ 3
(67.5 vs 64.6 %, p = 0.21; adjusted OR (95 % CI) = 1.21
(0.92–1.58), p = 0.16).
Discussion
This is the first study to evaluate the role of NLR on
periprocedural MI in patients undergoing non-urgent PCI.
Our main finding is that higher NLR increases the risk of
periprocedural MI; this applies especially for NLR ≥ 3.
In the last decades, various efforts have been made to im-
prove the outcome in patients with coronary artery disease,
by shortening the time to treatment in acute myocardial
infarction and introducing new techniques for the percuta-
neous treatment of more and more complex lesions [15–17].
However, despite the great reduction in mortality observed,
especially in the setting of STEMI, suboptimal results have
still been obtained in certain subsets of high-risk patients
[18–21]. Therefore, in recent years, great efforts have been
focused on the prevention of periprocedural complications.
In effect, periprocedural myocardial injury has been shown
by MRI studies to occur in the majority of PCI procedures
[22], thus requiring the identification of new biomarkers to
improve risk stratification.
Inflammation is a well-established risk factor for coro-
nary artery disease, playing a role in the progression of
atherosclerosis and regulating the process leading to the
“instabilisation” of a plaque, and then to an acute ischaemic
event [23]. Moreover, inflammatory response has been
strictly linked to an enhanced pro-thrombotic status, by in-
creasing the circulating levels of fibrinogen and other coag-
ulative factors and by enhancing platelet reactivity through
reactive oxygen species, cytokines and other mediators [24].
Many studies have evaluated the prognostic role of inflam-
matory biomarkers in cardiovascular disease, with contrast-
ing results [25]. Initial studies showed that an elevated to-
tal white blood cell count was associated with increased
mortality and worse outcomes after acute MI, and mainly
for patients with higher neutrophil counts [26]. More re-
cently, attention shifted to the NLR, combining the effects
of the nonspecific inflammatory response, mediated by neu-
470 Neth Heart J (2016) 24:462–474
Tab. 1 Clinical and demographic characteristics neutrophil/lymphocyte ratio quintiles











Age (mean ± SD) 64.7 ± 10.8 66.9 ± 10.8 66.6 ± 11.3 69.2 ± 10.6 70.5 ± 11.3 <0.001
Male sex (%) 76 76.6 79 77.2 73.7 0.54
Arterial hypertension (%) 70.4 74.9 75.2 70.1 72.4 0.02
Diabetes mellitus (%) 38.6 32.6 38.8 36.3 35.3 0.68
Hypercholesterolaemia (%) 64.6 63 63.5 53.8 46.8 <0.001
Smokers (%) 0.001
Active smokers 26.9 26.2 26.3 23.6 20.5
Previous smoker 27.7 27 28.6 19.9 21.5
Renal failure (%) 20.3 22.8 21.9 23.2 25.8 0.09
History of MI (%) 27.2 29.1 27.2 24.5 23.6 0.1
Previous PCI (%) 35.4 33.3 30 27 24.6 <0.001
Previous CABG (%) 11.6 15.4 13.7 14.8 12.6 0.82
Indication to angiography (%) 0.003
Stable angina 32.4 30.1 31.4 19.4 8.9
Acute coronary syndrome 63.2 62.7 62 76.9 84.6
LV dysfunction/Arrhythmia 4.4 7.1 6.6 3.8 6.5
Therapy at admission
ACE inhibitors (%) 44.1 42.9 44.4 46.2 39.6 0.5
ARB (%) 23.4 24.7 26.4 23.1 22 0.55
Beta blockers (%) 65.8 63.2 59 60.1 46.9 <0.001
Nitrates (%) 40.8 44.8 49.1 49.3 33.2 0.23
Calcium antagonists (%) 24.3 25.2 28.6 22.6 21.5 0.30
Diuretics (%) 26.8 23.8 32.2 33 36.3 0.001
Statins (%) 68.8 63.9 61.8 57.4 40.9 <0.001
Acetylsalicylic acid (%) 74.9 73.6 71.5 63.5 51.6 <0.001
Clopidogrel (%) 29 34 30.7 35.6 22.4 0.17
Main chemistry
Glycaemia (mg/dl ± SD) 128.3 ± 50.7 122.2 ± 46.8 129.7 ± 58 131.9 ± 49.6 148.4 ± 65.5 <0.001
Creatinine (mg/dl ± SD) 0.99 ± 0.56 1.06 ± 0.67 1.11 ± 0.73 1.09 ± 0.67 1.33 ± 1.17 <0.001
Platelets (103/ml; mean ± SD) 210.6 ± 58 213.3 ± 53 210.6 ± 58.8 213.4 ± 63.5 217.7 ± 82.9 0.52
Haemoglobin (g/d ± SD l) 13.7 ± 1.6 13.7 ± 1.5 13.5 ± 1.7 13.2 ± 1.8 12.9 ± 2 <0.001
WBC (103/ml; mean ± SD) 7.3 ± 2.8 7.3 ± 1.9 7.5 ± 1.9 8.3 ± 2.4 10.2 ± 3.5 <0.001
HbA1c (mmol/l ± SD) 47.6 ± 15.4 45.6 ± 13.7 46.1 ± 13.1 45.6 ± 12.7 45.7 ± 14.7 0.32
HDL cholesterol (mg/dl) 39.6 ± 11.1 39.5 ± 11.2 40.4 ± 11.6 38.8 ± 11.5 39.2 ± 12.1 0.38
Total cholesterol (mg/dl ± SD) 160.7 ± 42.3 160.6 ± 43.4 160.8 ± 40.2 161.5 ± 43.8 156.9 ± 40.7 0.61
Fibrinogen (mg/dl ± SD) 399 ± 116 418 ± 127 420 ± 117 461 ± 165 479 ± 193 <0.001
C-reactive protein (mg/dl ± SD) 0.52 ± 0.1 0.78 ± 0.19 0.86 ± 0.2 1.53 ± 0.15 3 ± 0.49 <0.001
trophils, and the subsequent regulatory immune response,
involving lymphocytes.
Indeed, neutrophils have been claimed to be responsi-
ble for each step leading to acute coronary events and in
addition, a low lymphocyte count has also been associated
with worse prognosis in patients with ischemic heart disease
and unstable angina [27], as a certain subset of lymphocytes
has been shown to play an inhibitory role in atherosclero-
sis, possibly by controlling and regulating the inflammatory
response [28].
In fact, NLR has been associated with indirect indicators
of atherosclerosis, such as the coronary calcium score, and
to the extent of angiographically defined coronary artery
disease [8]. Moreover, NLR has emerged as a predictor
of clinical outcome in both stable patients undergoing per-
cutaneous or surgical coronary revascularisation [29] and
in patients with acute coronary syndrome [30], with the
majority of studies conducted in the setting of acute myo-
cardial infarction. In particular, Ergelen et al. reported in
a large cohort of STEMI patients that NLR levels >6.97
were associated with increased in-hospital and long-term
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Tab. 2 Angiographic and procedural characteristics neutrophil/lymphocyte ratio quintiles











Severe CAD (%)a 25 32 32.7 28.8 37.9 0.009
Multivessel disease (%) 54.4 63 56.8 56 63.7 0.17
GP IIb/IIIa inhibitors a 44.3 43.3 39.8 47.2 43.1 0.78
Clopidogrel bolus > 6 h
pre-PCI a
21.5 22.4 25.7 25.7 16.5 0.1
Multivessel PCI a 23.2 25.6 27.4 22.9 23.5 0.79
Lesion length (mm ± SD) 22 ± 13.7 20.8 ± 13.7 21.6 ± 13.7 21.5 ± 12.9 21.4 ± 14.8 0.82
Target vessel diameter (mm ±
SD)
3 ± 0.6 3 ± 0.6 3 ± 0.6 3 ± 0.6 3 ± 0.6 0.88
% Stenosis (± SD) 89.7 ± 9.5 87.8 ± 10.2 88.8 ± 10 90.4 ± 9.3 90.6 ± 9.5 <0.001
Target vessel 0.65
Right coronary artery (%) 21 18.9 22.6 22.5 20.4
Left main (%) 3 2 3 1.1 1.9
Left anterior descending (%) 29.6 31.1 25.6 28.1 27.2
Circumflex branch (%) 16.1 16 16.7 13.4 16.4
Saphenous venous graft (%) 2.6 4.2 3 2.8 2.7
Anterolateral branch (%) 11.1 11.8 13.2 13.4 11.6
Type C lesions (%) 31.4 25.1 29.9 32.4 33.8 0.12
Eccentric plaques (%) 97.9 98.9 97.6 98.1 97.9 0.69
Calcifications (%) 10 14 18.5 17.8 16.2 0.005
Thrombus (%) 6.9 3.4 6.5 14.8 17.5 <0.001
TIMI flow pre-PCI <3 (%) 24.3 21.3 22.6 26.5 33.2 <0.001
In-stent restenosis (%) 8.2 8 5.5 5.1 5.5 0.04
Chronic occlusion (%) 7.9 6.6 9.4 7.1 6 0.42
Bifurcations (%) 23.9 26.6 28.1 20.6 20.4 0.06
Pre-dilatation (%) 64.9 64.4 62.1 72.7 64.6 0.32
Direct stenting (%) 28.5 28 28.7 20.5 27.8 0.18
Drug-eluting stents (%) 71.2 65.7 65.8 62.4 59.9 0.001
Max inflation (atm ± SD) 21.6 ± 3.7 21 ± 3.5 20.9 ± 4.1 20.7 ± 3.6 21 ± 3.4 0.06
Kissing balloon (%) 18.2 14.3 16.6 14.6 11.6 0.05
Thrombectomy (%) 2.1 1.7 2.4 3.6 7.4 <0.001
TIMI post PCI <3 (%) 20.8 21.8 19.3 22.5 26.7 0.003
Any dissection (%) 1.3 1.4 1.8 1.1 0.6 0.35
Slow flow (%) 2.6 1.4 1.5 2.2 4.2 0.12
Coronary perforation (%) 1.3 2.2 0.8 1.1 0.8 0.27
Distal embolisation (%) 1 0.6 1.5 1.4 2 0.16
Additional stent required (%) 1 1.1 2.2 1.6 2 0.24
Side branch loss (%) 0.8 0.8 0.7 1.1 0 0.36
aPer patient definition
cardiovascular mortality, and similar results were reported
in a Korean population of patients undergoing primary PCI
[11, 31]. However, so far few studies have evaluated the
role of NLR in patients undergoing elective percutaneous
coronary revascularisation.
In our study we observed a relevant impact of elevated
NLR on periprocedural MI in a large population of pa-
tients undergoing elective PCI, as all acute patients un-
derwent pharmacological stabilisation before coronary an-
giography. Indeed, confirming previous findings, higher
NLR has been associated with acute coronary syndrome,
intracoronary thrombus and other inflammatory parameters,
such as C-reactive protein and fibrinogen; however, our pos-
itive association between NLR and periprocedural MI was
maintained at multivariate analysis even after correction for
potential confounders. Moreover, using the ROC curve we
identified NLR ≥ 3 as being best for predicting the risk of
periprocedural MI.
Similar results were obtained by Akpet and colleagues,
although in a population of STEMI patients, reporting that
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an NLR > 3.3 had a 74 % specificity and 83 % sensitivity
to predict the phenomenon of no-reflow [32], an event that
has been associated to a larger infarct size and a worse
prognosis in patients undergoing primary PCI.
Analogous results were reported by Soylu et al. linking
NLR to the no-reflow development in patients undergoing
primary PCI [33]. In addition, Yilmaz et al. identified
a significant association between this inflammatory marker
and the presence of intracoronary thrombus [10], which
has been demonstrated to increase the risk of distal em-
bolisation and impaired myocardial perfusion in patients
undergoing PCI. In this context, the extensive use of po-
tent antiplatelet drugs, such as abciximab and other GP IIb/
IIIa inhibitors in our patients, could have influenced throm-
bus burden and then prevented a large number of events,
although no difference in administration of GP IIb/IIIa in-
hibitors was observed across the NLR quintiles.
Therefore, future studies are certainly needed to evaluate
whether lowering NLR can prevent periprocedural myocar-
dial injury after PCI and whether these effects can con-
tribute to the myocardial protection proposed for certain
drugs, such as for acetylsalicylic acid and especially for
statins [34, 35]. In fact, in our study they were signifi-
cantly inversely related to NLR, an association that can be
explained by the pleiotropic, anti-inflammatory effects of
statins, rather than their hypolipaemic effect.
Study limitations
A first limitation to our study can be considered the inclu-
sion of a cohort of patients who were heterogeneous for cer-
tain clinical baseline characteristics, including risk factors
as older age, hyperglycaemia, acute presentation or previ-
ous revascularisation, which are known per se to influence
the occurrence of periprocedural MI. We observed a rela-
tively high rate of periprocedural MI, which could be ex-
plained by the large number of complex, high-risk patients,
including those with acute coronary syndrome. The lower
rate of events among stable patients could have contributed
to the lack of significance of the association between NLR
and periprocedural MI in this context.
However, the aim of the present study was to assess the
impact of NLR in a real-life population of patients under-
going PCI and in addition, the independent relationship of
NLR and periprocedural MI was confirmed even after cor-
rection for potential confounders. Even though the great-
est increase in periprocedural MI was observed in patients
with NLR in the IV and V quintiles, especially for values
above 3, as identified by the ROC curve analysis, no linear
relationship was observed between NLR and periprocedural
MI. Nevertheless, the association for this parameter with
NLR was quite weak, and certainly its impact in clinical
practice needs further confirmation.
In fact, we did not collect data from long-term follow-
up in our patients and therefore we cannot evaluate the
long-term prognostic impact of periprocedural myonecro-
sis and effects of NLR on outcome after stent implantation.
However, it has been advocated that periprocedural MI is
probably only of minor relevance for patient prognosis, and
especially for troponin elevation. The frequent increase in
troponin after PCI could have potentially masked the rela-
tionship with NLR, thus rendering its determination non-
specific.
In addition, we did not evaluate NLR changes after PCI,
although very modest changes in these parameters are usu-
ally observed in elective patients; this in contrast to STEMI
patients where the leukocyte profile at 24 hours after pri-
mary PCI, but not the baseline haematological indexes, has
been demonstrated to be an independent predictor of car-
diovascular outcome [8].
Finally, the use of intravascular imaging, as intravas-
cular ultrasound or optical coherence tomography, would
certainly have prevented periprocedural complications in
patients with suboptimal procedural results after coronary
stent implantation.
Conclusions
The present study is the first to demonstrate that in pa-
tients undergoing non-urgent PCI a higher NLR increases
the risk of periprocedural myocardial infarction, especially
for values ≥ 3.
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